Hematology Transfusion and Cell Therapy's 2026 Journal Metrics Score is 0.1, ranking Q4 in Genetics and 2 other subfields. Two-year citation average from OpenAlex data, updated August 2026.
Bookmark this page — track observed submission-to-acceptance timing, FWCI and field-normalized citation data for this journal in one view.
Journal Metrics Score 2026 · 2021–2024 window citedness 0.09.
Middle 50%: 111–246 days
99 of 100 PubMed-indexed articles · 99% coverage · 2024–2025
Hematology Transfusion and Cell Therapy accepts papers a median of 174 days after submission, including peer review and revisions. That is slower than 88% of comparable journals with PubMed timing data.
No journal-level APC is available in the current OpenAlex snapshot. Cost is excluded from scoring.
Paste your title to see which of this journal's published topics it overlaps with. Your title stays in your browser for this preview and is not sent anywhere.
Want ranked journals with fit reasons, risks and a submission strategy instead? See a sample AI report.
Each spoke is a 0–100 percentile within a comparable journal cohort—not a percentage grade or a single black-box rating.
13 of 7,056 works · same type, year & subfield
0 works · same type, year & subfield
Below field-year expectation
of 1,395 topic-associated OpenAlex sources by lifetime output
FWCI compares papers with the same publication year, type, and field. 1.0 is the world average; above 1.0 is above expectation. This journal's median is 0.00, so its typical recent paper runs about 100% below its field benchmark.
0.2% of recent papers rank in the global top 10% after field normalization. This is easier to compare across specialties than raw citation totals.
Volume is separated from citation accumulation so newer papers are not presented as weaker simply because they are newer.
OpenAlex source records · 2017–2025
7,056 OpenAlex works · 2021–2024
OpenAlex topics show the research communities this journal serves.
Candidates share at least one OpenAlex subfield (or field, if too few do) with this journal's main research topics, ignoring generic catch-all topics, and are ordered by topic overlap, then current Journal Metrics Score.
* Cost is indicative only. APCs, taxes, waivers, and member discounts can change—always verify on the journal's official website.
| Category | Quartile |
|---|---|
| Genetics | Q4 |
| Hematology | Q4 |
| Management of Technology and Innovation | Q4 |
A lower-cited Q4 journal by citation data
By citation data, Hematology Transfusion and Cell Therapy is in the lowest quartile in Genetics and 2 other subfields and ranks #5,998 of 6,272 Medicine journals by Journal Metrics Score (top 96%). A Q4 placement means its papers are cited less than most in the subfield; on its own it does not mean the journal is predatory or that its peer review is weak. Hematology Transfusion and Cell Therapy's 2026 Journal Metrics Score is 0.1. Recent papers took a median of 174 days from submission to acceptance, according to PubMed dates. OpenAlex classifies its papers in subfields including Genetics, Hematology, and Management of Technology and Innovation, so check that your topic fits its scope.
Verdict from citation data only: quartile and field rank by Journal Metrics Score (OpenAlex), publisher-reported acceptance rates, and PubMed submission and acceptance dates. See how we rank journals and how to verify indexing.
Confirm the exact title and ISSNs against the publisher homepage before a high-stakes submission decision.
Source: the current OpenAlex source record. OpenAlex works can include multiple work types. Fully Open Access is a source-level flag. Recent OA Works is summed from OpenAlex's counts_by_year series (up to the latest ten years); it is not a lifetime OA percentage. Any APC shown here is an indicative OpenAlex value—verify current charges on the journal's official website.
OpenAlex classifies Hematology Transfusion and Cell Therapy's papers in subfields including Genetics, Hematology, and Management of Technology and Innovation. Read the aims and scope page and a few recent papers close to your topic before you prepare the manuscript.
Article types, word and figure limits, reference style, and the required statements (data availability, ethics, conflicts of interest, author contributions) are set by the journal. Prepare the cover letter and files to match them.
Hematology Transfusion and Cell Therapy homepage ↗Most Elsevier and Cell Press journals take submissions through Editorial Manager; each journal has its own site, reached from Submit your article on the journal homepage.
The journal is fully open access, and OpenAlex has no article processing charge on record. Check the journal website for current fees and waivers.
Recent accepted papers took a median of 174 days from submission to acceptance, including revisions (PubMed dates). Hematology Transfusion and Cell Therapy does not publish an acceptance rate.
Submission system from the publisher's author information, checked 2026-10-27. Individual journals can differ, so follow the link in the journal's own author guidelines.
New on PubMed
Type a topic to see the newest PubMed papers from the past week and the big picture of what they found, summarized by Claude on the Pro plan. Get a free weekly email to keep up.
See a demo:GLP-1CRISPRLong COVID
Reviewer Two · coming soon
An AI pre-submission report on your manuscript: the objections a tough reviewer is likely to raise, desk-rejection risks, and better-fit journals from our data. $29 per report.
See what the report coversBy citation data, Hematology Transfusion and Cell Therapy is in the lowest quartile in Genetics and 2 other subfields and ranks #5,998 of 6,272 Medicine journals by Journal Metrics Score (top 96%). A Q4 placement means its papers are cited less than most in the subfield; on its own it does not mean the journal is predatory or that its peer review is weak. Hematology Transfusion and Cell Therapy's 2026 Journal Metrics Score is 0.1. Recent papers took a median of 174 days from submission to acceptance, according to PubMed dates. OpenAlex classifies its papers in subfields including Genetics, Hematology, and Management of Technology and Innovation, so check that your topic fits its scope.
Hematology Transfusion and Cell Therapy's 2026 Journal Metrics Score is 0.1, from the August 2026 data release. The score is a two-year citation average computed from OpenAlex (CC0) data: citations received in the most recent complete year to works published in the two prior years, divided by the number of those works.
We have not found an official acceptance rate published by Hematology Transfusion and Cell Therapy or its publisher, and Journal Metrics does not estimate one because submission counts are not public. What recent PubMed records do show is speed: accepted papers took a median of 174 days from submission to acceptance. To judge selectivity, compare Hematology Transfusion and Cell Therapy's quartile and score with similar journals, or ask the editorial office.
Hematology Transfusion and Cell Therapy's best quartile is Q4. By OpenAlex subfield: Q4 in Genetics; Q4 in Hematology; Q4 in Management of Technology and Innovation. Quartiles rank journals by Journal Metrics Score within each subfield.
No. Journal Metrics computes the score independently from OpenAlex open data. Other providers use different citation databases, document types, and counting rules, so their published figures for Hematology Transfusion and Cell Therapy will not match this score exactly. Compare journals using one source at a time.
Hematology Transfusion and Cell Therapy accepts papers a median of 174 days after submission across 99 recent PubMed records with both dates; the middle half took 111–246 days. This includes peer review, editorial handling, and revisions.
PubMed records when a manuscript was received and accepted, not the individual review stages, so peer review time on its own is not available. The full time from submission to acceptance at Hematology Transfusion and Cell Therapy, which includes peer review and revisions, has a median of 174 days. For the time to a first decision, check the journal's own website.
Hematology Transfusion and Cell Therapy's median of 174 days from submission to acceptance is slower than 88% of comparable journals with PubMed timing data.
Comparable journals include Indian Journal of Hematology and Blood Transfusion, Hematology-American Society of Hematology Education Program, Lancet Haematology, and Blood Reviews. Compare their scores, acceptance times, and costs in the recommended alternatives on this page before choosing where to submit.
Most Elsevier and Cell Press journals take submissions through Editorial Manager; each journal has its own site, reached from Submit your article on the journal homepage. Before submitting, check the scope, follow the author guidelines for article type, length, and required statements, and prepare a cover letter. Accepted papers took a median of 174 days from submission to acceptance in recent PubMed records.